APA (7th ed.) Citation

S, S., E, S., E, D., A, M., M, C., M, E., . . . AM, B. (2024). Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: IPHARMGx Master Protocol and PREVESTATGx nested clinical trial. BMJ open, 14(11), e089823. https://doi.org/10.1136/bmjopen-2024-089823

Chicago Style (17th ed.) Citation

S, Stewart, et al. "Phase IV Adaptive Randomised Clinical Trials Evaluating Efficacy and Cost-efficacy of Pre-emptive Pharmacogenetic Genotyping Strategies in the Spanish National Health System: IPHARMGx Master Protocol and PREVESTATGx Nested Clinical Trial." BMJ Open 14, no. 11 (2024): e089823. https://doi.org/10.1136/bmjopen-2024-089823.

MLA (9th ed.) Citation

S, Stewart, et al. "Phase IV Adaptive Randomised Clinical Trials Evaluating Efficacy and Cost-efficacy of Pre-emptive Pharmacogenetic Genotyping Strategies in the Spanish National Health System: IPHARMGx Master Protocol and PREVESTATGx Nested Clinical Trial." BMJ Open, vol. 14, no. 11, 2024, p. e089823, https://doi.org/10.1136/bmjopen-2024-089823.